Is the greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes achieved in patients presenting with ST-segment changes : the Enoxaparin in Non-Q-Wave Coronary Events ( ESSENCE ) Electrocardiogram Core Laboratory Substudy?
Specific recognition of patients with ST-segment depression appears to identify those not only at high risk for adverse outcome, but also patients most likely to derive the greatest benefit from enoxaparin, as compared with UFH therapy.
DeAgrs effectively inhibit TNF-α-mediated leukocyte adhesion in vitro by breaking up hydrophobic lipophilic interactions, thus may be further tested for blocking atherogenesis.